-
-
-
-
-
-
-
Gilead Sciences (GILD) Announces U.S. FDA Accepts for Priority Review sBLA for Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer
-
-
-
-
-
-
-
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
-
-
-
-
-
-
-
Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma Study
-
-
-
-
-
-
-
Gilead Sciences Announces Third Quarter 2017 Financial Results
-
-
-
-
-
-
-
Gilead Sciences (GILD), Kite Pharma (KITE) Announce Expiration of HSR Waiting Period
-
-
-
-
-
-
-
Gilead Sciences (GILD) Announces European CHMP Adopts Positive Opinion for Vosevi for Treatment of All Chronic Hepatitis C Genotypes
-
-
-
-
-
-
-
Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection
-
12,335 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All